Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs VMC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VMC's multiple
Needs VMC P/E.
Implied fair value · at HRMY's multiple
Needs HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · VMC FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
VULCAN MATERIALS COMPANY · implied price per share
Bear
$107.88
Base
$126.92
Bull
$145.96
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.51x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
1.66x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$187.41M
Total debt
Interest-bearing obligations outstanding
$163.66M
$4.36B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
EAGLE MATERIALS INC
HRMY vs EXP
CEMEX SAB DE CV
HRMY vs CX
MARTIN MARIETTA MATERIALS INC
HRMY vs MLM
Summit Materials, Inc.
HRMY vs SUM
GRANITE CONSTRUCTION INC
HRMY vs GVA
MOHAWK INDUSTRIES INC
HRMY vs MHK
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY's higher-growth, higher-margin profile deserves at least some rerating toward VMC multiples, then HRMY looks attractive relative to VMC because the current price of $37.26 is far below VMC-implied range of $74.32-$102.47 and still within its own historical/DCF bands.
HRMY trades at a much lower valuation than VMC despite stronger growth and better margins, implying the market is assigning a significantly lower multiple to HRMY's earnings stream. The P/E-based implied price of $101.31 versus the current $37.26 suggests a large discount to VMC framework.
Supporting Metrics
